Rosli Rosliana, Ming Long Chiau, Abd Aziz Noorizan, Manan Mohamed Mansor
Department of Pharmacy Practice, Faculty of Pharmacy, Universiti Teknologi MARA, Puncak Alam, Selangor, Malaysia.
Unit for Medication Outcomes Research and Education (UMORE), Pharmacy, School of Medicine, University of Tasmania, Hobart, Australia.
PLoS One. 2016 Jun 1;11(6):e0155385. doi: 10.1371/journal.pone.0155385. eCollection 2016.
Spontaneous reporting on adverse drug reactions (ADR) has been established in Malaysia since 1987, and although these reports are monitored by the Malaysia drug monitoring authority, the National Pharmaceutical Control Bureau, information about ADRs in the paediatric patient population still remains unexplored. The aims of this study, therefore, were to characterize the ADRs reported in respect to the Malaysian paediatric population and to relate the data to specific paediatric age groups.
Data on all ADRs reported to the National Pharmaceutical Control Bureau between 2000 and 2013 for individuals aged from birth to 17 years old were analysed with respect to age and gender, type of reporter, suspected medicines (using the Anatomical Therapeutic Chemical classification), category of ADR (according to system organ class) as well as the severity of the ADR.
In total, 11,523 ADR reports corresponding to 22,237 ADRs were analysed, with half of these reporting one ADR per report. Vaccines comprised 55.7% of the 11,523 ADR reports with the remaining being drug related ADRs. Overall, 63.9% of ADRs were reported for paediatric patients between 12 and 17 years of age, with the majority of ADRs reported in females (70.7%). The most common ADRs reported were from the following system organ classes: application site disorders (32.2%), skin and appendages disorders (20.6%), body as a whole general disorders (12.8%) and central and peripheral nervous system disorders (11.2%). Meanwhile, ADRs in respect to anti-infectives for systemic use (2194/5106; 43.0%) were the most frequently reported across all age groups, followed by drugs from the nervous system (1095/5106; 21.4%). Only 0.28% of the ADR cases were reported as fatal. A large proportion of the reports were received from healthcare providers in government health facilities.
ADR reports concerning vaccines and anti-infectives were the most commonly reported in children, and are mainly seen in adolescents, with most of the ADRs manifesting in skin reactions. The majority of the ADR reports were received from nurses in the public sector, reporting ADRs associated with vaccine administration. The low fatality rate of ADR cases reported could potentially be caused by reporting bias due to the very low reporting percentage from the private healthcare institutions. This study indicates that ADR rates among Malaysian children are higher than in developed countries. Constant ADR reporting and monitoring, especially in respect to paediatric patients, should be undertaken to ensure their safety.
马来西亚自1987年起建立了药品不良反应(ADR)自发报告制度,尽管这些报告由马来西亚药品监管机构国家药品控制局进行监测,但有关儿科患者群体中ADR的信息仍未得到充分探索。因此,本研究的目的是描述针对马来西亚儿科人群报告的ADR特征,并将数据与特定儿科年龄组相关联。
对2000年至2013年间向国家药品控制局报告的所有出生至17岁个体的ADR数据,按年龄和性别、报告者类型、可疑药物(使用解剖治疗化学分类)、ADR类别(根据系统器官分类)以及ADR的严重程度进行分析。
共分析了11,523份ADR报告,对应22,237例ADR,其中一半报告每份报告有一例ADR。疫苗占11,523份ADR报告的55.7%,其余为药物相关的ADR。总体而言,63.9%的ADR报告是针对12至17岁的儿科患者,其中大多数ADR报告来自女性(70.7%)。报告的最常见ADR来自以下系统器官类别:用药部位疾病(32.2%)、皮肤及附属器疾病(20.6%)、全身一般性疾病(12.8%)以及中枢和周围神经系统疾病(11.2%)。同时,全身用抗感染药的ADR(2194/5106;43.0%)在所有年龄组中报告最为频繁,其次是神经系统药物(1095/5106;21.4%)。只有0.28%的ADR病例报告为致命。很大一部分报告来自政府卫生机构的医疗服务提供者。
关于疫苗和抗感染药的ADR报告在儿童中最为常见,主要见于青少年,大多数ADR表现为皮肤反应。大多数ADR报告来自公共部门的护士,报告与疫苗接种相关的ADR。报告的ADR病例低死亡率可能是由于私立医疗机构报告率极低导致的报告偏倚。本研究表明,马来西亚儿童的ADR发生率高于发达国家。应持续进行ADR报告和监测,尤其是针对儿科患者,以确保他们的安全。